Cnidarian Peptide Neurotoxins: a New Source of Various Ion Channel
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Anemonia Viridis Venom: Coupling Biochemical Purification
marine drugs Review The Anemonia viridis Venom: Coupling Biochemical Purification and RNA-Seq for Translational Research Aldo Nicosia 1,*,† , Alexander Mikov 2,†, Matteo Cammarata 3, Paolo Colombo 4 , Yaroslav Andreev 2,5, Sergey Kozlov 2 and Angela Cuttitta 1,* 1 National Research Council-Institute for the Study of Anthropogenic Impacts and Sustainability in the Marine Environment (IAS-CNR), Laboratory of Molecular Ecology and Biotechnology, Capo Granitola, Via del mare, Campobello di Mazara (TP), 91021 Sicily, Italy 2 Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, GSP-7, ul. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; [email protected] (A.M.); [email protected] (Y.A.); [email protected] (S.K.) 3 Department of Earth and Marine Sciences, University of Palermo, 90100 Palermo, Italy; [email protected] 4 Istituto di Biomedicina e di Immunologia Molecolare, Consiglio Nazionale delle Ricerche, Via Ugo La Malfa 153, 90146 Palermo, Italy; [email protected] 5 Institute of Molecular Medicine, Ministry of Healthcare of the Russian Federation, Sechenov First Moscow State Medical University, 119991 Moscow, Russia * Correspondence: [email protected] (A.N.); [email protected] (A.C.); Tel.: +39-0924-40600 (A.N. & A.C.) † These authors have made equal contribution. Received: 29 September 2018; Accepted: 24 October 2018; Published: 25 October 2018 Abstract: Blue biotechnologies implement marine bio-resources for addressing practical concerns. The isolation of biologically active molecules from marine animals is one of the main ways this field develops. Strikingly, cnidaria are considered as sustainable resources for this purpose, as they possess unique cells for attack and protection, producing an articulated cocktail of bioactive substances. -
Venom Gland Transcriptomic and Proteomic
toxins Article Venom Gland Transcriptomic and Proteomic Analyses of the Enigmatic Scorpion Superstitionia donensis (Scorpiones: Superstitioniidae), with Insights on the Evolution of Its Venom Components Carlos E. Santibáñez-López 1, Jimena I. Cid-Uribe 1, Cesar V. F. Batista 2, Ernesto Ortiz 1,* and Lourival D. Possani 1,* 1 Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad 2001, Apartado Postal 510-3, Cuernavaca, Morelos 62210, Mexico; [email protected] (C.E.S.-L.); [email protected] (J.I.C.-U.) 2 Laboratorio Universitario de Proteómica, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad 2001, Apartado Postal 510-3, Cuernavaca, Morelos 62210, Mexico; [email protected] * Correspondence: [email protected] (E.O.); [email protected] (L.D.P.); Tel.: +52-777-329-1647 (E.O.); +52-777-317-1209 (L.D.P.) Academic Editor: Richard J. Lewis Received: 25 October 2016; Accepted: 1 December 2016; Published: 9 December 2016 Abstract: Venom gland transcriptomic and proteomic analyses have improved our knowledge on the diversity of the heterogeneous components present in scorpion venoms. However, most of these studies have focused on species from the family Buthidae. To gain insights into the molecular diversity of the venom components of scorpions belonging to the family Superstitioniidae, one of the neglected scorpion families, we performed a transcriptomic and proteomic analyses for the species Superstitionia donensis. The total mRNA extracted from the venom glands of two specimens was subjected to massive sequencing by the Illumina protocol, and a total of 219,073 transcripts were generated. -
Aspartic Acid Isomerization Characterized by High Definition
toxins Article Aspartic Acid Isomerization Characterized by High Definition Mass Spectrometry Significantly Alters the Bioactivity of a Novel Toxin from Poecilotheria Stephen R. Johnson 1,2,* and Hillary G. Rikli 3 1 Carbon Dynamics Institute LLC, Sherman, IL 62684, USA 2 Chemistry Department, University of Illinois Springfield, Springfield, IL 62703, USA 3 College of Liberal Arts & Sciences, University of Illinois Springfield, Springfield, IL 62703, USA; [email protected] * Correspondence: [email protected] Received: 2 March 2020; Accepted: 23 March 2020; Published: 25 March 2020 Abstract: Research in toxinology has created a pharmacological paradox. With an estimated 220,000 venomous animals worldwide, the study of peptidyl toxins provides a vast number of effector molecules. However, due to the complexity of the protein-protein interactions, there are fewer than ten venom-derived molecules on the market. Structural characterization and identification of post-translational modifications are essential to develop biological lead structures into pharmaceuticals. Utilizing advancements in mass spectrometry, we have created a high definition approach that fuses conventional high-resolution MS-MS with ion mobility spectrometry (HDMSE) to elucidate these primary structure characteristics. We investigated venom from ten species of “tiger” spider (Genus: Poecilotheria) and discovered they contain isobaric conformers originating from non-enzymatic Asp isomerization. One conformer pair conserved in five of ten species examined, denominated PcaTX-1a and PcaTX-1b, was found to be a 36-residue peptide with a cysteine knot, an amidated C-terminus, and isoAsp33Asp substitution. Although the isomerization of Asp has been implicated in many pathologies, this is the first characterization of Asp isomerization in a toxin and demonstrates the isomerized product’s diminished physiological effects. -
Scorpion Toxin Peptide Scaffolds
Toxins 2013, 5, 2456-2487; doi:10.3390/toxins5122456 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Article Evolution Stings: The Origin and Diversification of Scorpion Toxin Peptide Scaffolds Kartik Sunagar 1,2,†, Eivind A. B. Undheim 3,4,†, Angelo H. C. Chan 3, Ivan Koludarov 3,4, Sergio A. Muñoz-Gómez 5, Agostinho Antunes 1,2 and Bryan G. Fry 3,4,* 1 CIMAR/CIIMAR, Centro Interdisciplinar de Investigação Marinha e Ambiental, Universidade do Porto, Rua dos Bragas, 177, 4050-123 Porto, Portugal; E-Mails: [email protected] (K.S.); [email protected] (A.A.) 2 Departamento de Biologia, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, 4169-007, Porto, Portugal 3 Venom Evolution Lab, School of Biological Sciences, The University of Queensland, St. Lucia, Queensland 4072, Australia; E-Mails: [email protected] (E.A.B.U.); [email protected] (A.H.C.C.); [email protected] (I.K.) 4 Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland 4072, Australia 5 Department of Biochemistry and Molecular Biology, Centre for Comparative Genomics and Evolutionary Bioinformatics, Dalhousie University, Halifax, Nova Scotia, Canada; E-Mail: [email protected] † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +61-400-193-182. Received: 21 November 2013; in revised form: 9 December 2013 / Accepted: 9 December 2013 / Published: 13 December 2013 Abstract: The episodic nature of natural selection and the accumulation of extreme sequence divergence in venom-encoding genes over long periods of evolutionary time can obscure the signature of positive Darwinian selection. -
Modifications to the Harmonized Tariff Schedule of the United States To
U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b). -
Expression, Delivery and Function of Insecticidal Proteins Expressed by Recombinant Baculoviruses
Viruses 2015, 7, 422-455; doi:10.3390/v7010422 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Expression, Delivery and Function of Insecticidal Proteins Expressed by Recombinant Baculoviruses Jeremy A. Kroemer 1,2, Bryony C. Bonning 1 and Robert L. Harrison 3,* 1 Department of Entomology, Iowa State University, Ames, IA 50011, USA; E-Mails: [email protected] (J.A.K.); [email protected] (B.C.B.) 2 Current location and contact information: Monsanto Company, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA 3 USDA-ARS Beltsville Agricultural Research Center, Invasive Insect Biocontrol & Behavior Laboratory, 10300 Baltimore Ave, Beltsville, MD 20705, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-301-504-5249; Fax: +1-301-504-5104. Academic Editor: John Burand and Madoka Nakai Received: 25 November 2014 / Accepted: 15 January 2015 / Published: 21 January 2015 Abstract: Since the development of methods for inserting and expressing genes in baculoviruses, a line of research has focused on developing recombinant baculoviruses that express insecticidal peptides and proteins. These recombinant viruses have been engineered with the goal of improving their pesticidal potential by shortening the time required for infection to kill or incapacitate insect pests and reducing the quantity of crop damage as a consequence. A wide variety of neurotoxic peptides, proteins that regulate insect physiology, degradative enzymes, and other potentially insecticidal proteins have been evaluated for their capacity to reduce the survival time of baculovirus-infected lepidopteran host larvae. Researchers have investigated the factors involved in the efficient expression and delivery of baculovirus-encoded insecticidal peptides and proteins, with much effort dedicated to identifying ideal promoters for driving transcription and signal peptides that mediate secretion of the expressed target protein. -
Marine Drugs ISSN 1660-3397 © 2006 by MDPI
Mar. Drugs 2006, 4, 70-81 Marine Drugs ISSN 1660-3397 © 2006 by MDPI www.mdpi.org/marinedrugs Special Issue on “Marine Drugs and Ion Channels” Edited by Hugo Arias Review Cnidarian Toxins Acting on Voltage-Gated Ion Channels Shanta M. Messerli and Robert M. Greenberg * Marine Biological Laboratory, 7 MBL Street, Woods Hole, MA 02543, USA Tel: 508 289-7981. E-mail: [email protected] * Author to whom correspondence should be addressed. Received: 21 February 2006 / Accepted: 27 February 2006 / Published: 6 April 2006 Abstract: Voltage-gated ion channels generate electrical activity in excitable cells. As such, they are essential components of neuromuscular and neuronal systems, and are targeted by toxins from a wide variety of phyla, including the cnidarians. Here, we review cnidarian toxins known to target voltage-gated ion channels, the specific channel types targeted, and, where known, the sites of action of cnidarian toxins on different channels. Keywords: Cnidaria; ion channels; toxin; sodium channel; potassium channel. Abbreviations: KV channel, voltage-gated potassium channel; NaV, voltage-gated sodium channel; CaV, voltage-gated calcium channel; ApA, Anthopleurin A; ApB, Anthopleurin B; ATX II, Anemone sulcata toxin II; Bg II, Bunodosoma granulifera toxin II; Sh I, peptide neurotoxin I from Stichodactyla helianthus; RP II, polypeptide toxin II from Radianthus paumotensis; RP III, polypeptide toxin III from Radianthus paumotensis; RTX I, neurotoxin I from Radianthus macrodactylus; PaTX, toxin from Paracicyonis actinostoloides; Er I, peptide toxin I from Entacmaea ramsayi; Da I, peptide toxin I from Dofleinia armata; ATX III, Anemone sulcata toxin III; ShK, potassium channel toxin from Stichodactyla helianthus; BgK, potassium channel toxin from Bunodosoma granulifera; AsKS, kalciceptine from Anemonia sulcata; HmK, potassium channel toxin from Heteractis magnifica; AeK, potassium channel toxin from Actinia equina; AsKC 1-3, kalcicludines 1-3 from Anemonia sulcata; BDS-I, BDS-II, blood depressing toxins I and II Mar. -
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
I Regulations
23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products. -
Conotoxins As Tools to Understand the Physiological Function of Voltage-Gated Calcium (Cav) Channels
marine drugs Review Conotoxins as Tools to Understand the Physiological Function of Voltage-Gated Calcium (CaV) Channels David Ramírez 1,2, Wendy Gonzalez 1,3, Rafael A. Fissore 4 and Ingrid Carvacho 5,* 1 Centro de Bioinformática y Simulación Molecular, Universidad de Talca, 3460000 Talca, Chile; [email protected] (D.R.); [email protected] (W.G.) 2 Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, 3460000 Talca, Chile 3 Millennium Nucleus of Ion Channels-Associated Diseases (MiNICAD), Universidad de Talca, 3460000 Talca, Chile 4 Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA 01003, USA; rfi[email protected] 5 Department of Biology and Chemistry, Faculty of Basic Sciences, Universidad Católica del Maule, 3480112 Talca, Chile * Correspondence: [email protected]; Tel.: +56-71-220-3518 Received: 8 August 2017; Accepted: 4 October 2017; Published: 13 October 2017 Abstract: Voltage-gated calcium (CaV) channels are widely expressed and are essential for the completion of multiple physiological processes. Close regulation of their activity by specific inhibitors and agonists become fundamental to understand their role in cellular homeostasis as well as in human tissues and organs. CaV channels are divided into two groups depending on the membrane potential required to activate them: High-voltage activated (HVA, CaV1.1–1.4; CaV2.1–2.3) and Low-voltage activated (LVA, CaV3.1–3.3). HVA channels are highly expressed in brain (neurons), heart, and adrenal medulla (chromaffin cells), among others, and are also classified into subtypes which can be distinguished using pharmacological approaches. Cone snails are marine gastropods that capture their prey by injecting venom, “conopeptides”, which cause paralysis in a few seconds. -
Bioactive Mimetics of Conotoxins and Other Venom Peptides
Toxins 2015, 7, 4175-4198; doi:10.3390/toxins7104175 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Review Bioactive Mimetics of Conotoxins and other Venom Peptides Peter J. Duggan 1,2,* and Kellie L. Tuck 3,* 1 CSIRO Manufacturing, Bag 10, Clayton South, VIC 3169, Australia 2 School of Chemical and Physical Sciences, Flinders University, Adelaide, SA 5042, Australia 3 School of Chemistry, Monash University, Clayton, VIC 3800, Australia * Authors to whom correspondence should be addressed; E-Mails: [email protected] (P.J.D.); [email protected] (K.L.T.); Tel.: +61-3-9545-2560 (P.J.D.); +61-3-9905-4510 (K.L.T.); Fax: +61-3-9905-4597 (K.L.T.). Academic Editors: Macdonald Christie and Luis M. Botana Received: 2 September 2015 / Accepted: 8 October 2015 / Published: 16 October 2015 Abstract: Ziconotide (Prialt®), a synthetic version of the peptide ω-conotoxin MVIIA found in the venom of a fish-hunting marine cone snail Conus magnus, is one of very few drugs effective in the treatment of intractable chronic pain. However, its intrathecal mode of delivery and narrow therapeutic window cause complications for patients. This review will summarize progress in the development of small molecule, non-peptidic mimics of Conotoxins and a small number of other venom peptides. This will include a description of how some of the initially designed mimics have been modified to improve their drug-like properties. Keywords: venom peptides; toxins; conotoxins; peptidomimetics; N-type calcium channel; Cav2.2 1. Introduction A wide range of species from the animal kingdom produce venom for use in capturing prey or for self-defense. -
The Discovery and Development of Analgesics: New Mechanisms, New Modalities
The discovery and development of analgesics: new mechanisms, new modalities Gillian Burgess, Dic Williams J Clin Invest. 2010;120(11):3753-3759. https://doi.org/10.1172/JCI43195. Review Series Despite intensive research into pain mechanisms and significant investment in research and development, the majority of analgesics available to prescribers and patients are based on mechanistic classes of compounds that have been known for many years. With considerable ingenuity and innovation, researchers continue to make the best of the mechanistic approaches available, with novel formulations, routes of administration, and combination products. Here we review some of the mechanisms and modalities of analgesics that have recently entered into clinical development, which, coupled with advances in the understanding of the pathophysiology of chronic pain, will hopefully bring the promise of new therapeutics that have the potential to provide improved pain relief for those many patients whose needs remain poorly met. Find the latest version: https://jci.me/43195/pdf Review series The discovery and development of analgesics: new mechanisms, new modalities Gillian Burgess and Dic Williams Pain Research Unit, Pfizer Global Research and Development, Sandwich Laboratories, Sandwich, United Kingdom. Despite intensive research into pain mechanisms and significant investment in research and development, the majority of analgesics available to prescribers and patients are based on mechanistic classes of compounds that have been known for many years. With considerable